“A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers”, J Infec Dis, vol. 180, pp. 290-8, 1999.
, “A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.”, J Infect Dis, vol. 180, no. 2, pp. 290-8, 1999.
, “A case-control-study of risk factors for homophiles influenza Type B disease in Navajo children”, AM J Trop Med Hug, vol. 60, pp. 263-6, 1999.
, “Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children”, Pediatr Infect Dis J, vol. 33, pp. 865-871, 2014.
, “Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults”, Vaccine, vol. 29, pp. 5666-5674, 2011.
, “Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.”, J Infect Dis, vol. 181, no. 2, pp. 725-8, 2000.
, “Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine”, J Infec Dis, vol. 181, pp. 11133-7, 2000.
, “Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.”, J Infect Dis, vol. 181, no. 3, pp. 1133-7, 2000.
, “Diarrhoeal diseases in the White Mountain Apaches: clinical studies.”, J Diarrhoeal Dis Res, vol. 13, no. 1, pp. 12-7, 1995.
, “Diarrhoeal diseases in the White Mountain Apaches: epidemiologic studies.”, J Diarrhoeal Dis Res, vol. 13, no. 1, pp. 18-28, 1995.
, “Effect of Different Vaccination Schedules on Excretion of Oral Poliovirus Vaccine Strains”, J Infect Dis, vol. 192, pp. 2092-2098, 2005.
, “The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.”, N Engl J Med, vol. 338, no. 20, pp. 1405-12, 1998.
, “Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.”, J Pediatr, vol. 136, no. 2, pp. 168-75, 2000.
, “Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.”, Vaccine, vol. 18, no. 18, pp. 1902-9, 2000.
, “Evaluation of a Single Dose of Half Strength Inactivated Influenza Vaccine in Healthy Adults”, Vaccine, vol. 20, pp. 1099-1105, 2002.
, “First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)”, J Infect Dis, vol. 210, pp. 1052-1061, 2014.
, “First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)”, J Infect Dis, vol. 207, pp. 240-247, 2013.
, “Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial.”, JAMA, vol. 285, no. 1, pp. 52-9, 2001.
, “How valid are clinical signs of dehydration in infants?”, J Pediatr Gastroenterol Nutr, vol. 22, no. 1, pp. 56-61, 1996.
, “Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming with an Antigenic Variant”, J Infec Dis, vol. 198, pp. 635-641, 2008.
, “Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women”, J Infect Dis, vol. 204, pp. 854-863, 2011.
, “Impact of Body Mass Index on Immunogenicity of Pandemic H1N1 Vaccine in Children and Adults”, J Infect Dis, vol. 210, pp. 1270-1274, 2014.
, “Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans”, J Infect Dis, vol. 211, pp. 518-528, 2015.
, “Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.”, Vaccine, vol. 21, no. 21-22, pp. 2933-47, 2003.
, “Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials”, Vaccine, vol. 21-22, pp. 2933-2947, 2003.
,